Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285:2944-71. https://www.ncbi.nlm.nih.gov/pubmed/29637711
2. Mor A, Segal Salto M, Katav A, Barashi N, Edelshtein V, Manetti M, et al. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. Ann Rheum Dis. 2019;78:1260-8. https://www.ncbi.nlm.nih.gov/pubmed/31129606
3. Segal-Salto M, Barashi N, Katav A, Edelshtein V, Aharon A, Hashmueli S, et al. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Rep. 2020;2:100064. https://www.ncbi.nlm.nih.gov/pubmed/32039405
4. Greenman R, Snir T, Levi O, Katav A, Lawler J, Thorburn D, et al. The role of CCL24 in primary sclerosing cholangitis: bridging patient serum proteomics to preclinical data. Cells. 2024;13(3):209. https://pubmed.ncbi.nlm.nih.gov/38334601/
5. Tabibian JH, Ali AH, Lindor KD. Primary sclerosing cholangitis, part 1: epidemiology, etiopathogenesis, clinical features, and treatment. Gastroenterol Hepatol (N Y). 2018;14:293-304. https://www.ncbi.nlm.nih.gov/pubmed/29991937